Marine Drugs (Jan 2023)

Fast and Sustained Axonal Growth by BDNF Released from Chitosan Microspheres

  • Inmaculada Aranaz,
  • Niuris Acosta,
  • Julia Revuelta,
  • Agatha Bastida,
  • Víctor Gómez-Casado,
  • Concepción Civera,
  • Leoncio Garrido,
  • Eduardo García-Junceda,
  • Ángeles Heras,
  • Andrés R. Alcántara,
  • Alfonso Fernández-Mayoralas,
  • Ernesto Doncel-Pérez

DOI
https://doi.org/10.3390/md21020091
Journal volume & issue
Vol. 21, no. 2
p. 91

Abstract

Read online

Brain-derived neurotrophic factor (BDNF) regulates dendritic branching and dendritic spine morphology, as well as synaptic plasticity and long-term potentiation. Consequently, BDNF deficiency has been associated with some neurological disorders such as Alzheimer’s, Parkinson’s or Huntington’s diseases. In contrast, elevated BDNF levels correlate with recovery after traumatic central nervous system (CNS) injuries. The utility of BDNF as a therapeutic agent is limited by its short half-life in a pathological microenvironment and its low efficacy caused by unwanted consumption of non-neuronal cells or inappropriate dosing. Here, we tested the activity of chitosan microsphere-encapsulated BDNF to prevent clearance and prolong the efficacy of this neurotrophin. Neuritic growth activity of BDNF release from chitosan microspheres was observed in the PC12 rat pheochromocytoma cell line, which is dependent on neurotrophins to differentiate via the neurotrophin receptor (NTR). We obtained a rapid and sustained increase in neuritic out-growth of cells treated with BDNF-loaded chitosan microspheres over control cells (p < 0.001). The average of neuritic out-growth velocity was three times higher in the BDNF-loaded chitosan microspheres than in the free BDNF. We conclude that the slow release of BDNF from chitosan microspheres enhances signaling through NTR and promotes axonal growth in neurons, which could constitute an important therapeutic agent in neurodegenerative diseases and CNS lesions.

Keywords